199 related articles for article (PubMed ID: 26542058)
1. ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer.
Manna S; Bostner J; Sun Y; Miller LD; Alayev A; Schwartz NS; Lager E; Fornander T; Nordenskjöld B; Yu JJ; Stål O; Holz MK
Clin Cancer Res; 2016 Mar; 22(6):1421-31. PubMed ID: 26542058
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
[TBL] [Abstract][Full Text] [Related]
3. A novel compound LingH2-10 inhibits the growth of triple negative breast cancer cells in vitro and in vivo as a selective inverse agonist of estrogen-related receptor α.
Ning Y; Chen H; Du Y; Ling H; Zhang L; Chen L; Qi H; Shi X; Li Q
Biomed Pharmacother; 2017 Sep; 93():913-922. PubMed ID: 28715872
[TBL] [Abstract][Full Text] [Related]
4. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ERK signaling for treatment of ERRα positive TNBC.
Musheyev D; Miller E; Birnbaum N; Miller E; Erblich S; Schuck A; Alayev A
PLoS One; 2023; 18(5):e0283047. PubMed ID: 37163498
[TBL] [Abstract][Full Text] [Related]
6. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
7. Androgen Receptor in Stage I-II Primary Breast Cancer -Prognostic Value and Distribution in Subgroups.
Niméus E; Folkesson E; Nodin B; Hartman L; Klintman M
Anticancer Res; 2017 Dec; 37(12):6845-6853. PubMed ID: 29187464
[TBL] [Abstract][Full Text] [Related]
8. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
[TBL] [Abstract][Full Text] [Related]
9. Endocan as a prognostic biomarker of triple-negative breast cancer.
Sagara A; Igarashi K; Otsuka M; Kodama A; Yamashita M; Sugiura R; Karasawa T; Arakawa K; Narita M; Kuzumaki N; Narita M; Kato Y
Breast Cancer Res Treat; 2017 Jan; 161(2):269-278. PubMed ID: 27888420
[TBL] [Abstract][Full Text] [Related]
10. Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation Strategy.
Hellwig B; Madjar K; Edlund K; Marchan R; Cadenas C; Heimes AS; Almstedt K; Lebrecht A; Sicking I; Battista MJ; Micke P; Schmidt M; Hengstler JG; Rahnenführer J
PLoS One; 2016; 11(12):e0167585. PubMed ID: 27926932
[TBL] [Abstract][Full Text] [Related]
11. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
Hopp TA; Weiss HL; Parra IS; Cui Y; Osborne CK; Fuqua SA
Clin Cancer Res; 2004 Nov; 10(22):7490-9. PubMed ID: 15569979
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
13. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
Berns EM; Klijn JG; van Putten WL; de Witte HH; Look MP; Meijer-van Gelder ME; Willman K; Portengen H; Benraad TJ; Foekens JA
J Clin Oncol; 1998 Jan; 16(1):121-7. PubMed ID: 9440732
[TBL] [Abstract][Full Text] [Related]
14. The orphan nuclear receptor estrogen-related receptor beta (ERRβ) in triple-negative breast cancer.
Fernandez AI; Geng X; Chaldekas K; Harris B; Duttargi A; Berry VL; Berry DL; Mahajan A; Cavalli LR; Győrffy B; Tan M; Riggins RB
Breast Cancer Res Treat; 2020 Feb; 179(3):585-604. PubMed ID: 31741180
[TBL] [Abstract][Full Text] [Related]
15. PGC-1β regulates HER2-overexpressing breast cancer cells proliferation by metabolic and redox pathways.
Victorino VJ; Barroso WA; Assunção AK; Cury V; Jeremias IC; Petroni R; Chausse B; Ariga SK; Herrera AC; Panis C; Lima TM; Souza HP
Tumour Biol; 2016 May; 37(5):6035-44. PubMed ID: 26602383
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen suppresses brain metastasis of estrogen receptor-deficient breast cancer by skewing microglia polarization and enhancing their immune functions.
Wu SY; Sharma S; Wu K; Tyagi A; Zhao D; Deshpande RP; Watabe K
Breast Cancer Res; 2021 Mar; 23(1):35. PubMed ID: 33736709
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.
Reijm EA; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; van Gelder ME; Sieuwerts AM; Sleijfer S; Foekens JA; Berns EM
Breast Cancer Res Treat; 2011 Jan; 125(2):387-94. PubMed ID: 20306127
[TBL] [Abstract][Full Text] [Related]
18. ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer.
Madhavan S; Gusev Y; Singh S; Riggins RB
J Exp Clin Cancer Res; 2015 May; 34(1):45. PubMed ID: 25971350
[TBL] [Abstract][Full Text] [Related]
19. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
20. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
Berns EM; Klijn JG; Look MP; Grebenchtchikov N; Vossen R; Peters H; Geurts-Moespot A; Portengen H; van Staveren IL; Meijer-van Gelder ME; Bakker B; Sweep FC; Foekens JA
Clin Cancer Res; 2003 Apr; 9(4):1253-8. PubMed ID: 12684392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
